NEW YORK – UK-based Tagomics said on Wednesday that is has raised £6.7 million ($8.5 million).
Calculus Capital led the round, joined by Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures, and the MEIF Proof of Concept and Early Stage Fund.
In a statement, the University of Birmingham spinout, launched in 2020, said it would use the funding to support R&D for its multiomic platform for finding biomarkers for cancer and other diseases. The platform adds DNA fragment analysis to genomic and epigenomic analyses.
Tagomics previously raised £1.6 million in pre-seed funding from IQ Capital and Start Codon as well as a grant from Innovate UK.
"The multiomic capabilities of Tagomics' approach enable more comprehensive insight into diseases such as cancer," CEO and Cofounder Jack Kennefick said in a statement. "These insights will enable us to develop simpler and more accurate means of diagnosing and treating patients."
Tagomics is the first Europe-based participant in the new Illumina Ventures Labs program, formerly the Illumina Accelerator.